• The purpose of T cell-mediated cancer immunotherapy is to reactivate these responses to a degree that results in tumor destruction without causing harmful effects on normal cells. (wikipedia.org)
  • Moffitt Cancer Center continues to distinguish itself as a world leader in the development of novel immunotherapy treatments, capitalizing on the natural power of the body's immune system to defend itself against the growth and spread of cancerous cells. (moffitt.org)
  • It is a phase 2b randomized trial of autologous dendritic cell immunotherapy (CMN-001) plus standard treatment for advanced renal cell carcinoma after a nephrectomy ( MCC 21083 ). (moffitt.org)
  • This CMN-001 is an autologous, tumor antigen-loaded dendritic cell immunotherapy. (moffitt.org)
  • We currently test the safety and tolerability of experimental immunotherapy vaccines to treat brain tumors and Alzheimer's. (cedars-sinai.edu)
  • Dendritic cell immunotherapy for patients with metastatic renal cell carcinoma: University of Tokyo experience. (nwbio.com)
  • Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study. (nwbio.com)
  • Cancer immunotherapy research has exploded in recent years. (aacr.org)
  • The third plenary session of the AACR Annual Meeting 2019 , titled "Manipulating the Immune System in Cancer Therapy," focused on recent advances in the field of immunotherapy. (aacr.org)
  • Several types of ACT round out the immunotherapy arsenal, including chimeric antigen receptor (CAR) T-cell therapy, T-cell receptor (TCR) therapy, and tumor-infiltrating lymphocyte (TIL) therapy. (aacr.org)
  • Tumor stem cell-targeted immunotherapy for metastatic melanoma -a randomized phase 3 clinical trial. (ca.gov)
  • Therapeutic Candidate or Device Tumor stem cell-targeted immunotherapy. (ca.gov)
  • However, one has always to keep in mind that many challenges do still exist such as what is the best sequence and timing of joint applications, what are the best immunotherapy approaches, how to overcome tumor resistances, what about healthy tissue cytotoxicity, or which biomarkers or matrices of biomarkers are most beneficial for patients stratification, just to mention the most burning ones. (frontiersin.org)
  • Immunotherapy is emerging as a new form to treat cancer by harnessing the activity of cytotoxic CD8 + T lymphocytes (CTLs) that specifically recognize tumor-associated antigens. (lifeboat.com)
  • Failed T cell-based immunotherapies in the presence of genomic alterations in antigen presentations pathways may be overcome by NK cell-based immunotherapy. (elifesciences.org)
  • T cell-based immunotherapy, such as immune checkpoint blockade or adoptive T cell transfer, is limited by the ability of T cells to detect major histocompatibility complex (MHC)-presented antigen by tumor cells. (elifesciences.org)
  • Natural killer (NK) cell-based immunotherapy may overcome genetic mechanisms of resistance to T cell-based immunotherapy through antigen- and MHC-independent recognition of malignant cells. (elifesciences.org)
  • Thus, addressing the presence of immunosuppressive myeloid cell populations in the periphery and tumor microenvironment of patients with cancer is likely to be required for effective NK cell-based immunotherapy. (elifesciences.org)
  • Breast tumor infiltrating lymphocytes (TIL) are enriched in tumor-specific cytotoxic T lymphocytes (CTL), and may represent a superior source of CTL compare to peripheral blood lymphocytes (PBL), for adoptive T cell immunotherapy of breast cancer. (utmb.edu)
  • These results may have important implications for the treatment of chemotherapy resistant breast cancer with active or adoptive immunotherapy. (utmb.edu)
  • 2019-004323-20 ) at the American Association for Cancer Research (AACR) annual meeting in April 2022 and at the annual meeting of the Association for Cancer Immunotherapy (CIMT) in May 2022. (pipelinereview.com)
  • ICT-107 is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens. (genengnews.com)
  • Rescuing melanoma epitope-specific cytolytic T lymphocytes from activation-induced cell death, by SP600125, an inhibitor of JNK: implications in cancer immunotherapy. (uchc.edu)
  • Immunotherapy is being investigated more and more for the treatment of prostate cancer, and although not many of these therapies are currently FDA-approved, mounting data shows promise. (urologytimes.com)
  • At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Susan F. Slovin, MD, PhD , gave a presentation on immunotherapy in advanced prostate cancer, 1 reiterating the significant impact that this mode of treatment has had on patients with this disease. (urologytimes.com)
  • Please highlight the main points from your talk on immunotherapy in advanced prostate cancer. (urologytimes.com)
  • What is very challenging about any sort of immunotherapy, and in particular the checkpoint inhibitors, is that you need to get the treating product or the immune cells into the tumor microenvironment, which in the case of prostate cancer, happens to be the bone. (urologytimes.com)
  • Immunotherapy based on the adoptive transfer of ex vivo expanded and activated autologous tumor-reactive lymphocytes can mediate tumor regression in cancer patients. (unimedizin-mainz.de)
  • We successfully applied this strategy to the human TAAs p53, gp100 and MDM2-specific TCRs as promising antigens-driven immunotherapy for both melanoma and hematologic malignancies. (unimedizin-mainz.de)
  • This joint (Frankfurt/Mainz, Dresden, Essen, Heidelberg) translational immunotherapy project aims to combine NK cells as effector cells with universal epitope-specific CAR (UniCAR) with tunable activity. (unimedizin-mainz.de)
  • Cancer immunotherapy has demonstrated remarkable efficacy by checkpoint modulation in a large variety of neoplasms. (unimedizin-mainz.de)
  • Rocapuldencel-T is an autologous dendritic cell immunotherapy for patients with metastatic renal cell carcinoma about which we have written previously. (shu.edu)
  • Vaccine strategies for cancer immunotherapy depend on the induction of dendritic cells (DC) in close proximity to T cells. (shu.edu)
  • Involving the direct use of whole cells or cellular material in patients, cell therapy is an umbrella term for many subdivisions of biological research, encompassing fields such as stem cell therapy, gene therapy and immunotherapy. (ddw-online.com)
  • Primary interests include clinical trials design and the design and analysis of biomarker and imaging studies especially in the areas of GI cancer, lymphoma, melanoma, transplant and cancer immunotherapy. (dukecancerinstitute.org)
  • Safety and efficacy of dendritic cell-based immunotherapy DCVAC /OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial. (clearityfoundation.org)
  • He has successfully translated his findings from the laboratory to the clinics and has conducted and led several large national immunotherapy clinical trials for brain tumors. (stanfordhealthcare.org)
  • Dr. Lim is a world leader in immunotherapy for brain tumors. (stanfordhealthcare.org)
  • In addition to being invited world-wide to give lectures and seminars, he has given platform presentations on the topics of immunotherapy for brain tumors, neurosurgical techniques and management of brain tumors at the American Society of Clinical Oncologists, American Academy of Neurological Surgeons, Radiological Society of North America, Annual Symposium on Brain and Spine Metastases, Congress of Neurological Surgeons, and other meetings. (stanfordhealthcare.org)
  • This occurs because each T cell is endowed with a highly specific receptor that can bind to an antigen present at the surface of another cell. (wikipedia.org)
  • The T cell receptor binds to a complex formed by a surface protein named "MHC" (major histocompatibility complex) and a small peptide of about 9 amino-acids, which is located in a groove of the MHC molecule. (wikipedia.org)
  • There a process named central tolerance eliminates the T cells that have a receptor recognizing an antigen present on normal cells of the organism. (wikipedia.org)
  • Immunotherapies include checkpoint inhibitory antibodies, chimeric antigen receptor (CAR) T-cells, cancer vaccines, and oncolytic viruses. (moffitt.org)
  • This is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4 and CD8 T cells lentivirally transduced to express a HER2-specific chimeric antigen receptor (CAR) and EGFRt, delivered by an indwelling catheter in the tumor resection cavity or ventricular system in children and young adults with recurrent or refractory HER2-positive CNS tumors. (fredhutch.org)
  • GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression. (uci.edu)
  • We therfore engineered NKT cells to express a chimeric antigen receptor (CAR) on their surface so that they directly kill NB tumor cells. (texaschildrens.org)
  • Chimeric antigen receptor (CAR)-T cell therapies are on the verge of becoming powerful immunotherapeutic tools for combating hematological diseases confronted with pressing medical needs. (nature.com)
  • Classical " CARs consist of an extracellular binding domain mostly derived from a monoclonal antibody fragment (single-chain variable fragment-scFv), which is linked to intracellular binding domains of the T-cell receptor complex. (nature.com)
  • Here, we demonstrate that NK cells (haNKs) engineered to express a PD-L1 chimeric antigen receptor (CAR) haNKs killed a panel of human and murine head and neck cancer cells at low effector-to-target ratios in a PD-L1-dependent fashion. (elifesciences.org)
  • Here, we describe the pre-clinical in vitro and in vivo study of irradiated haNK cells engineered to express a second-generation chimeric antigen receptor (CAR) targeting programmed death-ligand 1 (PD-L1). (elifesciences.org)
  • The candidate combines an autologous chimeric antigen receptor (CAR) T cell therapy targeting the oncofetal antigen Claudin-6 (CLDN6) with a CLDN6-encoding CAR-T cell amplifying RNA vaccine (CARVac). (pipelinereview.com)
  • Knockdown of T-bet expression in Mart-127-35 -specific T-cell-receptor-engineered human CD4(+) CD25(-) and CD8(+) T cells attenuates effector function. (uchc.edu)
  • Death receptor-independent activation-induced cell death in human melanoma antigen-specific MHC class I-restricted TCR-engineered CD4 T cells. (uchc.edu)
  • Inhibition of superoxide generation upon T-cell receptor engagement rescues Mart-1(27-35)-reactive T cells from activation-induced cell death. (uchc.edu)
  • We are seeing a tremendous amount of interest in using chimeric antigen receptor T [CAR T] cells as an immune approach in prostate cancer. (urologytimes.com)
  • So, among the challenges that everybody's looked at, with regard to chimeric antigen receptor T cells, or armored CAR T cells, which we like to call them sometimes, is that they need to be stable. (urologytimes.com)
  • In particular, chimeric antigen receptor (CAR) - patient T cells genetically engineered to express antigen receptors targeting cancer cells - and organoid technologies (tiny, self-organized three-dimensional tissue cultures derived from stem cells) will continue to disrupt the cell and gene therapy and regenerative medicine fields, translating early successes with liquid cancers to solid tumors and beyond. (corning.com)
  • Using HLA-A2.1 transgenic mice, we have demonstrated the feasibility of T-cell receptor (TCR) gene transfer into T cells to circumvent self-tolerance to the widely expressed human p53 and MDM2 TAAs. (unimedizin-mainz.de)
  • T-cell therapies based on chimeric antigen receptor (CAR) T-cells are widely employed for this purpose, as they have the capacity to proliferate within the patient after infusion and offer sustained functional immunity. (ddw-online.com)
  • We designed a lentiviral vector expressing a chimeric antigen receptor with specificity for the B-cell antigen CD19, coupled with CD137 (a costimulatory receptor in T cells [4-1BB]) and CD3-zeta (a signal-transduction component of the T-cell antigen receptor) signaling domains. (nih.gov)
  • A low dose (approximately 1.5×10(5) cells per kilogram of body weight) of autologous chimeric antigen receptor-modified T cells reinfused into a patient with refractory chronic lymphocytic leukemia (CLL) expanded to a level that was more than 1000 times as high as the initial engraftment level in vivo, with delayed development of the tumor lysis syndrome and with complete remission. (nih.gov)
  • Apart from the tumor lysis syndrome, the only other grade 3/4 toxic effect related to chimeric antigen receptor T cells was lymphopenia. (nih.gov)
  • Engineered cells persisted at high levels for 6 months in the blood and bone marrow and continued to express the chimeric antigen receptor. (nih.gov)
  • ATTAMAGE-A1.1: Phase I/II study of Autologous CD8+ and CD4+ Transgenic T cells expressing high affinity MAGE-A1-specific T-Cell Receptor (TCR) combined with Atezolizumab in patients with metastatic MAGE-A1 expressing cancer. (fredhutch.org)
  • BNT211 is a potential first-in-class therapeutic approach which comprises a synergistic combination of two of the Company's proprietary drug products, an autologous chimeric antigen receptor (CAR) T cell therapy targeting the oncofetal antigen Claudin-6 (CLDN6) and a CLDN6-encoding CAR-T cell amplifying RNA vaccine (CARVac). (jacksonnewsreporter.com)
  • Their modifications include adding a chimeric antigen receptor specific for B7-H3 and partnering with Fate Therapeutics to make four genetic modifications to these cells. (urotoday.review)
  • What we've done is we've been able to engineer natural killer cells and then we've added a chimeric antigen receptor specific for B7-H3. (urotoday.review)
  • Whereas each T cell recognizes a single antigen, collectively the T cells are endowed with a large diversity of receptors targeted at a wide variety of antigens. (wikipedia.org)
  • Adoptive cell therapy using engineered T-cell receptors (TCRs) targeting cancer-testis antigens, such as Melanoma-associated antigen 3 (MAGE-A3), is a potential approach for the treatment of NSCLC. (thno.org)
  • Transfusion of autologous tumor-specific CTLs 1-4 and blockade of T cell inhibitory receptors 5-7 have demonstrated to elicit durable clinical benefit in a significant proportion of patients with melanoma, leukemia, lymphoma and other cancers, who failed to respond to conventional treatments. (lifeboat.com)
  • The key to curing every single cancer, which is our goal, is to have receptors that can recognize the tumor but don't recognize the normal cells. (ajmc.com)
  • Receptors recognizing and then attacking normal cells is what can cause toxicity. (ajmc.com)
  • One way to achieve this is to genetically modify immune cells, mainly T cells and recently also natural killer (NK) cells, to express chimeric antigen receptors (CARs). (nature.com)
  • NK cells express germ-line receptors that are either stimulatory or inhibitory, and the summation of these signals determines activation status ( Caligiuri, 2008 ). (elifesciences.org)
  • The therapeutic candidate is administered as an infusion and constitutes autologous T cells genetically engineered to express T-cell receptors (TCR) targeting cancer cells expressing melanoma associated antigen 3 and 6 and is developed based on engineered autologous cell therapy (eACT) platform.It was under development for relapsed and refractory multiple myeloma. (globaldata.com)
  • Chimeric antigen receptors (CAR)-engineered T cells have demonstrated remarkable efficacy in patients with B-cell malignancies. (unimedizin-mainz.de)
  • Emerging data suggest that the combination of DC-based vaccination with other cancer therapies may fully unleash the potential of DC-based cancer vaccines and improve patient survival. (moffitt.org)
  • While many successful immunotherapeutic regimens have relied on checkpoint inhibition, other immunotherapeutic approaches, such as adoptive cellular therapies (ACT), the use of bispecific antibodies, and targeting components of the tumor microenvironment, are showing promise in a variety of cancer types. (aacr.org)
  • Therapeutic Candidate or Device Cryopreserved autologous TRAC locus 1XX BCMA-CAR T cells Indication Relapsed and Refractory Multiple Myeloma Therapeutic Mechanism Engineered T cells target and kill BCMA+ Myeloma cells Unmet Medical Need No durable treatments are available for RRMM and only ~30% of patients can access current BCMA CAR therapies. (ca.gov)
  • This is why this important component of cancer treatment should be combined with immune therapies to shift the balance toward immune activation against tumor cells. (frontiersin.org)
  • The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. (uci.edu)
  • Although only a handful of cell and gene therapies are on the market, FDA officials predicted in 2019 that the agency will receive more than 200 investigational new drug applications per year for cell and gene therapies, and that by 2025, it expects to have accelerated to 10 to 20 cell and gene therapy approvals per year. (ajmc.com)
  • In total, 3 CAR T-cell therapies are now on the market, all targeting the CD19 antigen. (ajmc.com)
  • Lately, CAR-NK cell therapies have also come into focus as novel therapeutic options to address hurdles related to CAR-T cell therapies, such as therapy-induced side effects. (nature.com)
  • In this review, we are going to take a closer look at the commercial CAR-T cell therapies, as well as on CAR-T and CAR-NK cell products, which are currently under evaluation in clinical trials, that are being conducted in Germany. (nature.com)
  • Minaris Regenerative Medicine is a global contract development and manufacturing organization (CDMO) for cell and gene therapies. (b3cnewswire.com)
  • PCT's competencies in autologous cell therapies, cell manufacturing, cell processing, and delivery make it ideally suited as a manufacturer for ImmunoCellular Therapeutics as we look forward to completing this Phase II trial and seek to secure a strategic partner in connection with a future potential Phase III trial for ICT-107 and its commercialization," states Manish Singh, Ph.D., ImmunoCellular Therapeutics president and CEO. (genengnews.com)
  • As such, preserving the integrity of sensitive samples is a daily challenge for cell culture laboratories in their search for innovative new therapies. (ddw-online.com)
  • For research purposes, autologous cell therapies are often favoured because they do not require immunological matching and are personalised to the patient. (ddw-online.com)
  • One area in which autologous therapies have shown particular potential is in the treatment of cancer. (ddw-online.com)
  • Immuno-oncology therapies typically use genetically modified T-cells to combat and kill cancerous tissue by identifying the cancer cells as a foreign body in need of attack. (ddw-online.com)
  • These innovative therapies rely on the use of techniques and technologies that minimise the risk of contamination and achieve the strictly-controlled, secure environment necessary for growing healthy, viable cells. (ddw-online.com)
  • While cell therapies show great promise in bringing innovative and much needed treatments to patients, there are a number of key issues currently limiting their broader adoption. (ddw-online.com)
  • Safety concerns over the administration of live cells to patients, uncertainties over the way in which these therapies should be regulated, unknown downstream effects and the need for sufficient investment to fully commercialise research are all challenges that must be overcome in order to accelerate further development of cell therapies. (ddw-online.com)
  • The regulations surrounding cell therapies must therefore be sufficiently broad to cover this wide range of therapeutic processes, while still safeguarding product safety and quality. (ddw-online.com)
  • From a manufacturing point of view, autologous cell therapies can be more challenging to produce than allogeneic cell therapies, as each dose is a single batch and is derived from a different source. (ddw-online.com)
  • Metastatic triple negative breast cancer (TNBC), urothelial, and non-small cell lung cancer (NSCLC) are solid tumor malignancies with abysmal survival rates following progression on initial therapies. (fredhutch.org)
  • DelveInsight's Testicular Cancer Pipeline analysis depicts a robust space with 5+ active players working to develop 5+ pipeline treatment therapies. (jacksonnewsreporter.com)
  • Promising Testicular Cancer Pipeline Therapies include Fentanyl sublingual spray, Cabazitaxel, and others. (jacksonnewsreporter.com)
  • The Testicular Cancer companies and academics are working to assess challenges and seek opportunities that could influence Testicular Cancer R&D. The Testicular Cancer therapies under development are focused on novel approaches to treat/improve Testicular Cancer. (jacksonnewsreporter.com)
  • 5+ key companies which are developing the therapies for Testicular Cancer. (jacksonnewsreporter.com)
  • Alicia Morgans interviews Nick Zorko, who shares his excitement about his team's work on natural killer (NK) cell therapies, specifically focusing on engineered NK cells to target the tumor marker B7-H3. (urotoday.review)
  • Dr. Zorko believes that NK cell therapies will be safer, more accessible, and possibly suitable for outpatient settings, which is particularly beneficial for prostate cancer patients who are often older and may have multiple comorbidities. (urotoday.review)
  • So the University of Minnesota is very focused on natural killer cell therapies. (urotoday.review)
  • So we think this is going to be a great target for treating prostate cancer with these cellular therapies. (urotoday.review)
  • Some localized melanomas may result from azathioprine, which acts synergistically with ultraviolet radiation, while T-cell depleting induction therapies may promote late stage tumors. (cdc.gov)
  • A large retrospective analysis from a single institution revealed an improved cancer-specific survival advantage, even with resection of more than one metastatic lesion. (medscape.com)
  • To view a multidisciplinary tumor board case discussion, see Memorial Sloan Kettering e-Tumor Boards: Metastatic Clear Cell Renal Cell Carcinoma . (medscape.com)
  • Surgical resection remains the only known effective treatment for localized renal cell carcinoma, and it also is used for palliation in metastatic disease. (medscape.com)
  • Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. (nwbio.com)
  • Babatz J, Röllig C, Löbel B, Folprecht G, Haack M, Günther H, Köhne CH, Ehninger G, Schmitz M, Bornhäuser M. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. (nwbio.com)
  • Cell therapy with autologous TILs is generally safe and clinically active and may constitute a new treatment strategy in metastatic lung cancer. (nature.com)
  • The treatment of metastatic renal cell carcinoma is problematic, and, whenever possible, patients should be directed to approved and controlled clinical trials. (medscape.com)
  • Matrix metalloproteinase-12 expression correlates with local recurrence and metastatic disease in non-small cell lung cancer patients. (findmedarticle.com)
  • This phase I/II trial studies the side effects of gene-modified immune cells (FH-MCVA2TCR) and to see how well they work in treating patients with Merkel cell cancer that has spread to other parts of the body (metastatic) or that cannot be removed by surgery (unresectable). (fredhutch.org)
  • Metastatic pancreatic cancer patients have a mean survival of 6 months following progression on initial first line chemotherapy. (fredhutch.org)
  • In a phase I trial, we seek to determine the safety and preliminary antitumor efficacy of this T cell therapy in patients with metastatic pancreatic ductal adenocarcinomas whose tumors express mesothelin and have progressed on prior chemotherapy. (fredhutch.org)
  • Dr. Lim's clinical interests include the treatment of benign and malignant brain tumors, with special interest in gliomas, meningiomas, metastatic tumors, and skull base tumors. (stanfordhealthcare.org)
  • However, systematic analysis of T cell immune responses to MAGE-A3 antigen and corresponding antigen-specific TCR is still lacking. (thno.org)
  • Although immune checkpoint blockade (ICB) reinvigorates anti-tumor immune responses by disrupting co-inhibitory T-cell signaling, relapse frequently occurs after ICB treatment and acquired resistance often emergence after initial response [ 4 ]. (thno.org)
  • This approach allows us to look into mechanisms of immunosuppression by which tumor cells circumvent native and adaptive immune responses. (bmj.com)
  • The analysis of cytokines demonstrated a decrease of serum tumor markers and the reduction of Treg response in the treatment arm, compared to the control arm, and the results suggest a combination of humoral and cell immune responses. (bmj.com)
  • It is now well established that human tumors express unique antigens, however tumor immune evasion mechanisms often prevent effective naturally occurring anti-tumor immune responses. (biomedcentral.com)
  • A variety of evidence suggests that spontaneous immune responses to autologous tumor-associated antigens affect the cure of malignant tumors, and that some antibodies in sera could influence cancer cells. (okayama-u.ac.jp)
  • Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma. (cdc.gov)
  • They're injecting HER2 pulsed dendritic cells (MCC 20915) made from the patient back into their breast tumor before chemotherapy. (moffitt.org)
  • Our basic research focuses on designing a dendritic cell (DC) vaccine targeting glioblastoma multiforme (GBM) cancer stem cells to delay or prevent recurrence following surgery, chemotherapy or radiation. (cedars-sinai.edu)
  • Addeo, A., Banna, G. L., Metro, G. & Di Maio, M. Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung cancer: a systematic review and literature-based meta-analysis. (nature.com)
  • The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with platinum-doublet chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). (uci.edu)
  • The purpose of the study is to assess the safety, tolerability, and efficacy of farletuzumab ecteribulin (MORAb-202) and compare it to Investigator's choice (IC) chemotherapy in female participants with platinum-resistant HGS ovarian, primary peritoneal, or fallopian tube cancer. (uci.edu)
  • For decades the only available cancer treatments were surgical resection as well as chemotherapy and/or radiotherapy [ 1 ]. (nature.com)
  • Patients receive lympho-depleting chemotherapy of standard regimen fludarabine and cyclophosphamide, followed 72 hours later by the infusion of the autologous CAR T cells. (urologytimes.com)
  • Immuno-oncology approaches have been found to be more effective at long-lasting tumour regression than alternatives such as surgery, radiotherapy, chemotherapy and targeted therapy (1,2). (ddw-online.com)
  • Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. (findmedarticle.com)
  • 1 line of systemic therapy in case of participants ineligible for high-dose chemotherapy and autologous Hematopoietic stem cell transplantation (HSCT). (who.int)
  • Dr. Lim is the Chair of the Department of Neurosurgery and a board-certified neurosurgeon specializing in brain tumors and trigeminal neuralgia. (stanfordhealthcare.org)
  • Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. (nwbio.com)
  • Therapeutic cancer vaccination seeks to elicit activation of tumor-reactive T cells capable of recognizing tumor-associated antigens (TAAs) and eradicating malignant cells. (lu.se)
  • Normally, potentially malignant cells are continuously eliminated by the immune system, but cancer cells can accumulate certain mutations, which allow them to escape these mechanisms [ 2 ]. (nature.com)
  • CAR-modified immune cells are expanded until sufficient cell numbers are attained and are adoptively transferred into the patient to fight malignant cells. (nature.com)
  • Based on the results of these studies, anti-RPL29 antibody could be a first-in-class molecular-targeted drug for the treatment of malignant tumors. (okayama-u.ac.jp)
  • In addition, the concentration of the anti-RPL29 antibody in sera can be a new diagnostic biomarker for the treatment of malignant tumors. (okayama-u.ac.jp)
  • Non-Hodgkin lymphomas are a heterogeneous group of disorders involving malignant monoclonal proliferation of lymphoid cells in lymphoreticular sites, including lymph nodes, bone marrow, the spleen, the liver, and the gastrointestinal tract. (msdmanuals.com)
  • Hodgkin Lymphoma Hodgkin lymphoma is a localized or disseminated malignant proliferation of cells of the lymphoreticular system, primarily involving lymph node tissue, spleen, liver, and bone marrow. (msdmanuals.com)
  • A preparative regimen is needed to remove any inhibitory immune cells, ie, regulatory T cells (Tregs) that may contribute to a hostile tumor microenvironment, thereby providing an intratumoral milieu that blocks immune cell penetration. (urologytimes.com)
  • With their ability to serve as valuable model systems for studying the tumor microenvironment, organoids are accelerating discovery efforts in cancer biology and enabling rapid screening of potential new therapeutics. (corning.com)
  • The theoretical basis for marrow failure includes primary defects in or damage to the stem cell or the marrow microenvironment. (medscape.com)
  • Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. (marketbeat.com)
  • ICT-107 targets multiple tumor associated antigens. (genengnews.com)
  • In some patients, the majority of the tumor-specific T cells recognize mutated antigens. (wikipedia.org)
  • Furthermore, in both CD8+ T cell populations the majority of the tumor-specific CTL exhibited a Th1 cytokine bias (IFN-γ high /IL-4 low ). (utmb.edu)
  • and MT-601 for the treatment of pancreatic cancer and lymphoma. (marketbeat.com)
  • Yescarta), a CAR T-cell therapy for adults with large B-cell non-Hodgkin lymphoma. (ajmc.com)
  • Kite Pharma, a subsidiary of Gilead, received an accelerated approval in July 2020 for brexucabtagene autoleucel (Tecartus) for adults with relapsed or refractory mantle cell lymphoma. (ajmc.com)
  • Overview of Lymphoma Lymphomas are a heterogeneous group of tumors arising in the reticuloendothelial and lymphatic systems. (msdmanuals.com)
  • Non-Hodgkin lymphoma is not one disease but rather a category of lymphocyte cancers with a number of subgroups largely divided into aggressive and indolent types. (msdmanuals.com)
  • Non-Hodgkin lymphoma is the 2nd most common cancer in HIV-infected patients Non-Hodgkin lymphoma AIDS-defining cancers in patients infected with HIV are Kaposi sarcoma Lymphoma, Burkitt (or equivalent term) Lymphoma, immunoblastic (or equivalent term) Lymphoma, primary, of central nervous system read more , and some AIDS patients present with lymphoma. (msdmanuals.com)
  • MAINZ, Germany I September 9, 2022 I BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") today presented positive follow-up data from its ongoing first-in-human Phase 1/2 trial evaluating the safety and efficacy of the Company's novel CAR-T cell therapy candidate, BNT211, in patients with relapsed or refractory advanced solid tumors. (pipelinereview.com)
  • Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. (nwbio.com)
  • While low radiation doses mostly seem to enhance immune cell infiltration into tumors, higher doses do induce immunogenic cancer cell death, and create an immune stimulatory micro-environment for the attracted immune cells. (frontiersin.org)
  • We identified the HLA-A2 restricted T cell epitopes from MAGE-A3 that could effectively induce the activation and cytotoxicity of CD8+ T cells using artificial APC in vitro . (thno.org)
  • The therapy (CLBS20, also known as NBS20) uses purified autologous CSCs, derived from a patient's own tumor and grown as a tumor cell line, as the antigen source of tumor-associated antigens to induce or enhance an anti-tumoral immune response. (bmj.com)
  • To induce an efficient anti-tumor response against the patients' own tumor cells, the encapsulated GM-CSF secreting cells are implanted subcutaneously at the site of tumor-cell vaccination. (b3cnewswire.com)
  • Therapeutic Candidate or Device The therapeutic product candidate is autologous CD34+ hematopoietic stem/progenitor cells (HSPC) transduced with the G1XCGD lentiviral vector. (ca.gov)
  • they include hematopoietic stem cells and adult and embryonic stem cells. (ajmc.com)
  • We describe laboratory-confirmed influenza A pandemic (H1N1) 2009 in 17 hospitalized recipients of a hematopoietic stem cell transplant (HSCT) (8 allogeneic) and in 15 patients with malignancy treated at 6 Australian tertiary centers during winter 2009. (cdc.gov)
  • The protective effect of seasonal influenza vaccination is reduced in patients with hematologic malignancy and recipients of an allogeneic hematopoietic stem cell transplant (HSCT) ( 5 , 6 ). (cdc.gov)
  • Low-power view of hematoxylin-eosin-stained bone marrow showing hypocellularity, with increased adipose tissue and decreased hematopoietic cells in the marrow space. (medscape.com)
  • The clinical presentation of patients with aplastic anemia includes signs and symptoms related to the decrease in bone marrow production of hematopoietic cells. (medscape.com)
  • The specific medications administered depend on the choice of therapy and whether it is supportive care only, immunosuppressive therapy, or hematopoietic cell transplantation. (medscape.com)
  • Low power, H and E showing a hypocellular bone marrow with increased adipose tissue and decreased hematopoietic cells in the marrow space. (medscape.com)
  • Central venous catheter placement is required before the administration of hematopoietic cell transplantation. (medscape.com)
  • The Breast Oncology Department , for example, has developed innovative clinical trials for vaccines that offer new ways to treat various types and stages of breast cancer and improve patient outcomes. (moffitt.org)
  • Dendritic cell vaccines can potentially be used to treat different cancer types. (moffitt.org)
  • Maturation and trafficking of monocyte-derived dendritic cells in monkeys: implications for dendritic cell-based vaccines. (nwbio.com)
  • Here, we demonstrated that intradermal administration of clinically relevant vaccines efficiently induces Trm cells specific for tumor-specific and self-antigens that accumulate in vaccinated and non-vaccinated skin. (lifeboat.com)
  • Here we demonstrated that a single intradermal administration of gene- or protein-based vaccines efficiently induces specific Trm cell responses against models of tumor-specific and self-antigens, which accumulated in vaccinated and distant non-vaccinated skin. (lifeboat.com)
  • A lot of what we've done has been predicated on various immunologic approaches that included carbohydrate, DNA, and naked DNA vaccines, as well as antibody drug conjugates directed against a variety of cell surface targets. (urologytimes.com)
  • Other challenges to this therapy include knowing the affinity of the CAR T cell for the antigen in question.Clearly, prostate-specific membrane antigen, or PSMA, has been a focal target for a variety of different approaches, including immunological approaches with vaccines and antibody-drug conjugates in addition to CAR T cells, and more recently, a theranostic approach with 177-lutetium PSMA-617. (urologytimes.com)
  • Experimental treatment approaches include vaccines and nonmyeloablative allogeneic peripheral blood stem cell transplantation. (medscape.com)
  • Roche will be collaborating with BioNTech to develop personalized vaccines based on BioNTech's mRNA products combined with Roche's PD-L1 checkpoint inhibitor, Tecentriq (atezolizumab), which was approved for bladder cancer in May 2016. (shu.edu)
  • Download instantly Cancer Vaccines - Methods and Protocols by Michael J.P. Lawman, Patricia D. Lawman. (booksca.ca)
  • Kalorama has been researching and examining the development of cancer vaccines for seven years. (kaloramainformation.com)
  • With a couple prophylactic vaccines for cervical cancer on the market, a few select therapeutic vaccine approvals and several therapeutic vaccines on a promising path to commercialization, the market could see a surge of regulatory activity and an influx of market opportunities. (kaloramainformation.com)
  • This Kalorama Information report - Emerging Cancer Vaccines: Forecasts, Developments and Pipeline Analysis - focuses on both preventive and therapeutic cancer vaccines in development. (kaloramainformation.com)
  • Specifically, cancers where there is current vaccines development are profiled. (kaloramainformation.com)
  • Several companies have promising research and development activities for cancer vaccines. (kaloramainformation.com)
  • Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. (nwbio.com)
  • Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. (nwbio.com)
  • Here, we present a cancer vaccination approach utilizing myeloid lineage reprogramming to directly convert cancer cells into tumor reprogrammed-antigen presenting cells (TR-APCs). (lu.se)
  • Thus, TR-APCs represent a cancer vaccination therapeutic strategy with broad implications for clinical immuno-oncology. (lu.se)
  • demonstrate for the first time in pre-clinical model systems that radiotherapy can be combined with vaccination with syngeneic whole-tumor cell vaccine generated by high hydrostatic pressure, mimicking in cancer patients autologous vaccine from their own tumor cells. (frontiersin.org)
  • Interestingly, vaccination-induced Trm cells strongly suppress the growth of melanoma, independently of circulating CD8 T cells, and were able to infiltrate melanoma tumors. (lifeboat.com)
  • Therefore, our work highlights the therapeutic potential of vaccination-induced Trm cells to achieve potent protection against skin malignancies. (lifeboat.com)
  • Moreover, clinically applicable vaccination strategies that efficiently establish Trm cell responses remain largely unexplored and are expected to strongly protect against tumors. (lifeboat.com)
  • Vaccination-induced Trm cells were largely resistant to in vivo intravascular staining and antibody-dependent depletion. (lifeboat.com)
  • Intradermal, but not intraperitoneal vaccination, generated memory precursors expressing skin-homing molecules in circulation and Trm cells in skin. (lifeboat.com)
  • Vaccination strategies eliciting CTL responses specific for tumor-specific and self-antigens have shown promising results in recent clinical trials. (lifeboat.com)
  • The latest addition to oncotherapy is the use of dendritic cell (DC) vaccine therapy. (moffitt.org)
  • A dendritic cell vaccine is a cross between a vaccine and a cell therapy. (moffitt.org)
  • Dendritic cells can be used as a vaccine by preparing together with either peptides or small portions of tumor antigens and they can then be injected into the body. (moffitt.org)
  • Now researchers at Moffitt are working to develop a dendritic cell vaccine targeting HER3, a protein involved in the growth and spread of many different cancer types. (moffitt.org)
  • The GBM cancer stem cell vaccine is cellular and consists of patients' autologous dendritic cells infused with tumor lysate from an allogenic glioblastoma cancer stem cell line. (cedars-sinai.edu)
  • Radiotherapy thereby acts as an adjuvant for the vaccine that contains many tumor-associated antigens (adjuvanticity plus antigenicity) ( Seitz et al. ). (frontiersin.org)
  • ImmunoCellular Therapeutics has decided to use Progenitor Cell Therapy (PCT) to produce its Phase II glioblastoma vaccine, ICT-107. (genengnews.com)
  • PCT's cGMP plant in Mountain View, CA, will serve as a second manufacturing site for this dendritic cell-based vaccine. (genengnews.com)
  • Novavax to Use Vivalis' Duck Embryonic Stem Cell Line for Vaccine. (genengnews.com)
  • Sellas reversed merged into Galena , a peptide vaccine company whose lead product, NeuVax, for breast cancer failed. (shu.edu)
  • In April 2010, the cancer vaccine market experienced one of the biggest achievements in the therapeutic vaccine treatment of cancer-the approval of the prostate cancer vaccine PROVENGE (TM). (kaloramainformation.com)
  • This, in addition to the success of cervical cancer vaccine products, has created a viable market for what was merely a speculative area just one decade ago. (kaloramainformation.com)
  • This area of medicine is a new frontier and many of the issues that face the cancer vaccine market are novel. (kaloramainformation.com)
  • In this case, CARs include a part specific for the GD2 molecule, which is present at high levels in NB tumors and has already led to promising results in clinical trials of GD2-targeted T cells in NB patients. (texaschildrens.org)
  • PCT served as primary manufacturer for Dendreon during seven years of clinical trials for its prostate cancer cell-based treatment, Provenge. (genengnews.com)
  • As part of our mission to eliminate cancer, MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers. (mdanderson.org)
  • Specifically, he is interested in the utilization of compounds with novel mechanisms of action in clinical trials for the treatment of these tumors. (mdanderson.org)
  • Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study Blood Cancer Journal 10 (10): 106,2020. (pennmedicine.org)
  • A child or young adult with a refractory or recurrent CNS tumor will have their tumor tested for HER2 expression by immunohistochemistry (IHC) at their home institution or at Seattle Children's Hospital. (fredhutch.org)
  • Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial Lancet Oncology 21 (10): 1317-1330,2020. (pennmedicine.org)
  • The cells used in transplantation can either be derived from an individual patient (autologous cell therapy) or from another donor (allogeneic cell therapy). (ddw-online.com)
  • High risk of acute pulmonary toxicity with both myeloablative and non-myeloablative total body irradiation-based conditioning for allogeneic stem cell transplantation. (dukecancerinstitute.org)
  • With few exceptions, stem cell transplantation is usually reserved for patients with aggressive lymphomas after incomplete remission or relapse. (msdmanuals.com)
  • Risk of localized tumors was stable over time after transplantation, but higher with azathioprine maintenance therapy (IRR=1.35, 95%CI 1.03-1.77). (cdc.gov)
  • The prognosis for patients with pancreatic cancer is very poor. (okayama-u.ac.jp)
  • Dr. Yasuhiro Miyake (Assistant Professor of Okayama University Hospital) with his colleagues have found the presence of anti-60S ribosomal protein L29 (RPL29) antibody in sera, and showed that the anti- recRPL29-peptides polyclonal antibody inhibited the proliferation of human pancreatic cancer Panc-1 cells via the down-regulation of Wnt/β-Catenin signaling pathway in a dose dependent manner. (okayama-u.ac.jp)
  • Recent studies showed the positive correlation between the concentration of anti-RPL29 antibody in sera of pancreatic cancer patient and its prognosis. (okayama-u.ac.jp)
  • We hope to have an opportunity to focus on different types of targets in solid tumors that will address high unmet needs in cancers like gastric cancer and colorectal cancer and pancreatic cancer, and ovarian and endometrial. (libsyn.com)
  • We have developed an engineered autologous T cell therapy targeting mesothelin, an antigen overexpressed by pancreatic cancer cells. (fredhutch.org)
  • Mutated genes contribute greatly to the immunogenicity of human tumors. (wikipedia.org)
  • This session was chaired by Padmanee Sharma, MD, PhD , professor in the Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center, who opened the plenary by highlighting the incredible breakthrough of checkpoint inhibitors, which are helping many patients to have durable responses. (aacr.org)
  • This approach has proven efficacious in some patients with epithelial cancers, and has been shown to synergize with checkpoint inhibition. (aacr.org)
  • To address this need, we will link an ImmuNEO module to the DKTK MASTER program that will include exome and transcriptome-sequenced patients on a pan-cancer basis who receive treatment with checkpoint modulators. (unimedizin-mainz.de)
  • And what's really interesting about B7-H3 is that it's very highly expressed on prostate cancers and fortunately many other cancers as well, but in the context of there's very low PD-L1 and checkpoint inhibitor expression on these same cancers. (urotoday.review)
  • Rosenberg is beginning to develop a library of TCRs that can recognize shared mutations in the hope of utilizing them for TCR T-cell therapy for patients across a variety of tumor types, especially those with common epithelial cancers. (aacr.org)
  • In this study, we comprehensively screened HLA-A2 restricted MAGE-A3 tumor epitopes and characterized the corresponding TCRs using in vitro artificial antigen presentation cells (APC) system, single-cell transcriptome and TCR V(D)J sequencing, and machine-learning. (thno.org)
  • Furthermore, the tumor-reactive TCRs with killing potency was screened and verified. (thno.org)
  • Importantly, T cells artificially expressing the MAGE-A3-Mp4 specific TCRs exhibited strong MAGE-A3+ tumor cell recognition and killing effect. (thno.org)
  • This work identified candidate TCRs potentially suitable for TCR-T design targeting HLA-A2 restricted MAGE-A3 tumor antigen. (thno.org)
  • We hypothesized that infusion of T cells that have been genetically modified to express affinity-optimized antigen-specific TCRs may help overcome these barriers. (biomedcentral.com)
  • Genes are inserted encoding a PSMA-targeted Centyrin CAR with an iCasp9-based safely switch and DHFR to purify CAR T Cells.These T stem cell memory cells have bone marrow homing capability that may be particularly relevant to bone tropic tumors, such as prostate cancer. (urologytimes.com)
  • Cabazitaxel is used to treat people with prostate cancer that has progressed despite treatment with docetaxel. (jacksonnewsreporter.com)
  • Unlike most T-cell based approaches, this project aims at treating prostate cancer with modified NK cells. (urotoday.review)
  • This treatment utilizes a patient's own immune system to recognize and attack cancer cells. (aacr.org)
  • The patient's newly engineered T cells will then be administered via the indwelling CNS catheter for two courses. (fredhutch.org)
  • Following the two courses, patient's will undergo a series of studies including MRI to evaluate the effect of the CAR T cells and may have the opportunity to continue receiving up to a total of six courses of CAR T cells if the patient has not had adverse effects and if more of their T cells are available. (fredhutch.org)
  • Cancer immunotherapies aim to support or boost the patient's immune system to enable the effective clearance of cancer cells. (nature.com)
  • First, T or NK cells are isolated from patient's or donor's blood. (nature.com)
  • If the mutated cell divides significantly, the resulting clonal population may be eliminated by a T lymphocyte response. (wikipedia.org)
  • Identification of these mutated antigens allows us to further study specific T cell activation using mixed lymphocyte reaction assays. (bmj.com)
  • The establishment and characterisation of paired autologous tumour cell line (MST-1) and tumour-infiltrating lymphocyte (TIL) culture from a tumour mass of a 14-year-old Taiwanese girl with soft tissue melanoma are described. (tmu.edu.tw)
  • Flow cytometric analysis of the tumour DNA content showed an index of 1.8 relative to normal peripheral blood lymphocyte DNA. (tmu.edu.tw)
  • Fig. 5: Change in phenotype and genotype of peripheral T cells after TIL infusion. (nature.com)
  • Prior to infusion of the CAR-modified immune cells, lymphodepletion is performed in most therapeutic settings to allow efficient cell engraftment [ 10 ]. (nature.com)
  • All 22 patients showed robust, dose-dependent CAR-T cell expansion after infusion with cell frequencies close to 10 9 total counts in dose level 2. (pipelinereview.com)
  • To better understand the immune profile of the T cell product and its fate post infusion, baseline and post infusion PBMCs were analyzed by flow cytometry evaluating memory and exhaustion markers (e.g. (biomedcentral.com)
  • Analysis of cytokine production and polyfunctionality reveal how polyfunctional CD8+ and CD4+ NY-ESO c259 -T cells evolve upon infusion and selectively regulate different cytokines, with patients displaying different degrees of polyfunctionality. (biomedcentral.com)
  • The results revealed the upregulation of several immunosuppressive markers, including PDL-1, on myeloma cells associated with poor prognosis and trafficking, as well as immunosuppression following T cell infusion. (biomedcentral.com)
  • Tumor-specific T cells are identified, expanded, and infused into the lymphodepleted patient, where they can help mediate tumor regression. (aacr.org)
  • In addition, intracranial progression is common during systemic treatments due to the inability to penetrate central nervous system (CNS) barriers, whereas the intracranial effects of cancer immunotherapies remain unclear. (bvsalud.org)
  • Our results indicate that cancer immunotherapies can prevent intracranial progression, maintaining long-term effects intracranially as well as systemically. (bvsalud.org)
  • Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. (marketbeat.com)
  • Their unique approach on cancer immunotherapies addresses a significant unmet medical need for patients with difficult-to-treat tumors. (b3cnewswire.com)
  • This GINAKIT2 phase 1 clinical trial, the first to use of genetically engineered NKT cells in humans, will evaluate the anti-tumor activity of GD2 specific CAR and interleukin-15 expressing autologous NKT cells. (texaschildrens.org)
  • Dr. Blumenschein's area of focus is in new drug development, adoptive T-cell therapy and multimodality therapy for the treatment of lung and head and neck cancers. (mdanderson.org)
  • He is leading the Adoptive T-cell Program with the goal of developing this class of therapeutics for the treatment of Lung and Head and Neck Cancers. (mdanderson.org)
  • The main goals of this study are to: - Find the recommended dose(s) of BT5528 that can be given safely to participants alone and in combination with nivolumab - Learn more about the side effects of BT5528 - Learn about how effective BT5528 is for the treatment of ovarian cancer, urothelial/bladder cancer, lung cancer (NSCLC), triple-negative breast cancer, head and neck cancer (HNSCC), and gastric/upper gastrointestinal cancer. (uci.edu)
  • Transcriptomic profiling of T-cell populations in non-muscle invasive and muscle invasive bladder cancer. (lu.se)
  • In vivo TR-APC induction elicits clonal expansion of cancer-specific T cells, establishes cancer-specific immune memory, and ultimately promotes leukemia eradication. (lu.se)
  • Autologous TILs were expanded ex vivo from minced tumors cultured with interleukin-2. (nature.com)
  • Similar to the experience of others, we've always been faced with the fact that we used to use retroviral vectors to generate the final CAR product and that there are challenges to in how to maximize the in vivo efficacy of the CAR T cell. (urologytimes.com)
  • Taken together, these data show that tumor lysate-pulsed mature DC can consistently restore tumor-specific lytic activity in non-cytotoxic breast cancer TIL. (utmb.edu)
  • Silencing of endogenous IL-10 in human dendritic cells leads to the generation of an improved CTL response against human melanoma associated antigenic epitope, MART-1 27-35. (uchc.edu)
  • Immunostaining revealed that major melanoma-associated antigens, such as S100 protein, HMB-45, melanotransferrin, chondroitin sulphate proteoglycan, and the gangliosides GD2 and GD3, were consistently expressed by the tumour tissue, severe combined immunodeficiency (SCID) mouse xenograft and derived cell lines. (tmu.edu.tw)
  • This observation and the expression of the major melanoma-associated antigens were all indicative of the melanocytic origin of MST-1 tumour. (tmu.edu.tw)
  • This PSMA 101 platform has resulted in an ongoing phase 1, dose-escalating multicenter trial that seeks to determine safety and tolerability of the CAR T cell. (urologytimes.com)
  • Their pre-clinical work has been published in the journal Cancer Immunology Research . (moffitt.org)
  • His work has appeared in Science Translational Medicine, Clinical Cancer Research, Lancet Oncology, Nature Immunology, and many more publications. (stanfordhealthcare.org)
  • We initiated a study to evaluate the antitumor efficacy of T cells engineered with an affinity-enhanced TCR specific for the NY-ESO-1 and LAGE-1 cancer testis antigens (NY-ESO c259 -T) in multiple myeloma (MM) patients with antigen-positive tumors in the setting of an autologous stem cell transplant (NCT01352286). (biomedcentral.com)
  • Some genes are expressed by tumor cells and not by normal cells. (wikipedia.org)
  • A class of genes, named cancer-germline genes, is expressed in a large variety of cancer cells but not in normal cells, with the exception of germline cells, which do not carry MHC molecules on their surface and therefore do not present the antigens. (wikipedia.org)
  • The transformed cells often express permanently some viral genes. (wikipedia.org)
  • In cancer patients, about one half of the highly tumor-specific antigens recognized by spontaneous T cell responses are encoded by mutated genes, the other half being encoded by cancer-germline genes. (wikipedia.org)
  • Cancer-germline genes are an important source of tumor-specific antigens. (wikipedia.org)
  • These genes are expressed in a significant fraction of tumors of many different histological types. (wikipedia.org)
  • While most of the neoantigens identified through these screening efforts have been unique, a few were common neoantigens that correspond to "hotspot mutations" in KRAS and p53, two genes that are frequently mutated in cancer. (aacr.org)
  • Besides modification based on a second-generation CAR, more advanced CAR-immune cell therapeutics are being tested, which utilize precise insertion of genes to circumvent graft-versus-host disease (GvHD) or employ a dual targeting approach and adapter CARs in order to avoid therapy resistance caused by antigen loss. (nature.com)
  • Subsequently, cells are transduced with CAR-encoding genes using (mostly) viral vectors. (nature.com)
  • CpG island methylation and expression of tumour-associated genes in lung carcinoma. (findmedarticle.com)
  • The Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis found 16 significant regulated pathways in imDCs and 10 significant regulated pathways in mDCs, including the phagosome, cell adhesion signaling pathway, and inflammatory mediator regulation of TRP channels pathway. (frontiersin.org)
  • Organoids are generated using tissue-specific stem cells, which are typically undifferentiated epithelial cells. (corning.com)
  • These dendritic cells are like immune system factories and make other molecules that activate critical parts of the innate and adaptive immune system. (moffitt.org)
  • The addition of separate adapter molecules (AMs) specific for tumor antigens and CAR-immune cells targeting these AMs allows a more precise and temporally limited therapy. (nature.com)
  • Promising combinations of UniCAR NK cells and distinct targeting molecules will be identified for subsequent translation into a phase clinical study. (unimedizin-mainz.de)
  • The rationale of this approach is to bypass mechanisms by which cancer cells dampen the anti-tumor immune response, including down-regulation of MHC Class I molecules. (shu.edu)
  • We have identified TCR sequences in CD8T cell clones which downstream analysis of antigen specificity will be assessed by the Denver team. (dtic.mil)
  • The UniCAR is only activated upon cross-linking through a soluble tumor-targeting module carrying the UniCAR binding epitope, thereby achieving highest tumor specificity. (unimedizin-mainz.de)
  • T cells and TCR will be obtained from blood and tumor tissue and tested for neoantigen specificity and tumor reactivity. (unimedizin-mainz.de)
  • To improve this therapeutic strategy, Rosenberg and colleagues developed a method to identify the exact antigens that the T cells could recognize. (aacr.org)
  • The therapeutic approach to renal cell carcinoma (RCC) is guided by the probability of cure, which is related directly to the stage or degree of tumor dissemination. (medscape.com)
  • Therapeutic Mechanism Destruction of host tumor stem cells by adaptive humoral cellular immunity will eradicate the origin of melanoma which will extend patient survival. (ca.gov)
  • Therapeutic Candidate or Device Tissue implant engineered using expanded, allogeneic chondroprogenitor cells Indication Defects of the temporomandibular joint disc complex Therapeutic Mechanism Though the mechanism has not been established, Hyaleon®️ may initially act as a load bearing structure that fills defects of the temporomandibular joint (TMJ) disc complex. (ca.gov)
  • Therapeutic Candidate or Device Rebecsinib is a novel small molecule inhibitor of ADAR1 splicing that selectively eradicates therapy-resistant cancer stem cells in blood cancers. (ca.gov)
  • Therapeutic Candidate or Device The therapeutic candidate is a patient specific (autologous) induced pluripotent stem cell derived retinal pigment epithelium (AiPSC-RPE) product. (ca.gov)
  • Previous work from the contributing DKTK partner sites has demonstrated the versatility of this approach in T cells, and showed that it is feasible to derive CAR-engineered, established human NK cells as an off-the-shelf cellular therapeutic. (unimedizin-mainz.de)
  • Therapeutic response correlates with the mutational load of the patient tumors, suggesting that neoantigens contribute to tumor rejection. (unimedizin-mainz.de)
  • In a phase I trial, we seek to determine the safety and potential efficacy of this T cell therapy in addition to an FDA approved therapeutic standard anti-PD-L1 therapeutic, atezolizumab, for patients with advanced triple negative breast cancer, urothelial, or non-small cell lung cancers whose tumors express high level of MAGE-A1 and have become resistant to PD-L1 axis treatments. (fredhutch.org)
  • We have a couple of other modifications that we've been able to make with our therapeutic partners as well, Fate Therapeutics, and that includes high affinity CD-16 that allows us to add a second monoclonal antibody to redirect the cells as well to give it a second kill signal. (urotoday.review)
  • We are currently enrolling patients on a phase 1 trial , GINAKIT2, to find the highest and safe dose of GD2-CAR NKT cells (GINAKIT cells) for subsequent study of their anti-tumor activity. (texaschildrens.org)
  • We hypothesize that CAR.GD2-IL15 NKTs will demonstrate anti-tumor activity in NB patients through a combination of directly killing NB cells and indirectly targeting supportive TAMs. (texaschildrens.org)
  • The results demonstrated encouraging signs of anti-tumor activity and the safety profile remained manageable for the two tested dose levels. (pipelinereview.com)
  • Antigenic peptides derived from the encoded proteins are therefore presented on the surface of tumor cells and not on normal cells. (wikipedia.org)
  • This leads to the presentation of viral antigenic peptides absent from normal cells. (wikipedia.org)
  • Using syngeneic murine leukemia models, we demonstrate that TR-APCs acquire both myeloid phenotype and function, process and present endogenous TAAs, and potently stimulate TAA-specific CD4+ and CD8+ T cells. (lu.se)
  • Treatment of syngeneic tumors resulted in CD8 and PD-L1-dependent tumor rejection or growth inhibition and a reduction in myeloid cells endogenously expressing high levels of PD-L1. (elifesciences.org)
  • Celgene acquired EngMab for $600MM to enrich its programs targeting B-cell maturation antigen (BCMA) for the treatment of multiple myeloma. (shu.edu)
  • CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model. (uchc.edu)
  • NK cells can enhance T-cell activation without production of cytokines linked to adverse reactions. (unimedizin-mainz.de)
  • In murine models, intracranial rechallenged tumors after initial rejection by PD-1 blockade were suppressed. (bvsalud.org)
  • Accordingly, long-lived memory precursor effector T cells and antigen-specific T cells were increased by PD-1 blockade in intracranial lesions. (bvsalud.org)
  • There are currently few consistently effective treatments for individuals with these cancers following treatment with PD-L1 axis blockade. (fredhutch.org)